|Chemical and physical data|
|Molar mass||407.451 g/mol g·mol−1|
|3D model (JSmol)|
Velneperit (S-2367) is a drug developed by Shionogi, which acts as a potent and selective antagonist for the Neuropeptide Y receptor Y5. It has anorectic effects and was developed as a possible treatment for obesity, but was discontinued from further development after disappointing results in Phase II clinical trials. However it was still considered a successful proof of concept of the potential of Y5 receptor antagonists as possible anti-obesity agents in future.
- Yukioka H. A potent and selective neuropeptide Y Y5-receptor antagonist, S-2367, as an anti-obesity agent. (Japanese). Nihon Yakurigaku Zasshi. 2010 Nov;136(5):270-4. PMID 21079365
- Oda S, et al. Development of an Optimized Synthetic and Purification Process of S-2367 (Velneperit), a Novel Neuropeptide Y (NPY) Y5 Receptor Antagonist. Org. Process Res. Dev. 2015; 19(4):531–536. doi: 10.1021/acs.oprd.5b00023
- George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity. J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):65-76. doi: 10.1177/1074248413501017 PMID 24064009
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|